Author | Number of patients | Type of study | Blinding | Time window to inclusion | Follow-up | Outcome | Adverse effects |
---|---|---|---|---|---|---|---|
Safa-Tisseront 2001 [8] | 527 (504 analyzed) | Therapeutic, prospective, non-randomised, observational | NA | 4 days (1–53) | 15 days | 75% complete relief, 18% incomplete relief, 7% failure | Fever in 3 patients |
Williams 1999 [12] | 55 (7 prophylactic, 41 therapeutic EDBP, 7 conservative treatment) | Retrospective, non-randomised, observational | NA | <1 week | ? | 34% complete relief, 54% incomplete relief, 12% failure | Back pain in 3 patients |
Banks 2001 [9] | 100 (81 pdph7 prophylactic, 58 therapeutic EDBP, 23 conservative treatment) | Prospective, non randomised, observational | NA | 0–3 days | ? | 67% complete relief, 28% incomplete relief, 5% failure | 22% back pain |
Taivainen 1993 [7] | 81 (55 patients 10 ml, 26 patients 10–15 ml EDBP) | Prospective, partly randomised, observational | NA | 0–10 days | 1 week | Initial relief 91%, permanent relief 61% | 25% back pain |
Vercauteren 1999 [11] | 190 (186 EDBP, 4 atypical symptoms) | Retrospective, non randomised | NA | >24 h after symptoms | 1 day | Initial relief 99%, permanent relief 73% | ? |
Stride 1993 [10] | 34819 (461 PDPH, 137 EDBP attempted, 135 completed) | Retrospective, non randomised | NA | 2 days | ? | Initial relief 90%, permanent Relief 64% | ? |
Seebacher 1989 [20] | 12 (6 EDBP, 6 sham treatment) | Prospective, randomised | Yes | >4 days | 1 day | EDBP 83% relief sham treatment 0% relief | Back pain |